Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Buys $12,910.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson purchased 1,000 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were purchased at an average cost of $12.91 per share, with a total value of $12,910.00. Following the transaction, the vice president now directly owns 264,148 shares in the company, valued at $3,410,150.68. This trade represents a 0.38 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Greenwich LifeSciences Stock Performance

Shares of GLSI stock opened at $13.94 on Tuesday. Greenwich LifeSciences, Inc. has a fifty-two week low of $8.00 and a fifty-two week high of $21.44. The firm has a market cap of $183.31 million, a P/E ratio of -17.42 and a beta of 1.62. The business’s 50 day moving average price is $13.80 and its 200-day moving average price is $14.43.

Institutional Trading of Greenwich LifeSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Garden State Investment Advisory Services LLC purchased a new position in Greenwich LifeSciences during the 3rd quarter valued at $253,000. Bank of New York Mellon Corp bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter valued at about $264,000. Rhumbline Advisers purchased a new position in shares of Greenwich LifeSciences during the second quarter valued at about $117,000. Barclays PLC raised its stake in Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after buying an additional 6,538 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares during the period. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright increased their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Friday, August 23rd.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.